

- NEW PROSPECTS IN CNS BIOMARKER DETECTION -






Ron Wacker, Joachim Dyck, Andreas Jonas and Michael Adler

Chimera Biotec GmbH, Emil-Figge-Str. 76a, 44227 Dortmund, Germany, Phone +49 231 9742 840, Fax +49 231 9742 844, wacker@chimera-biotec.com

Imperacer™ is a proprietary biomarker detection and monitoring technology focused on the analysis of low abundant and hardly detectable biomarkers. The Imperacer™ technology combines the advantages of immunoassays with the exponential signal amplification of PCR.

Imperacer™ Key Advantages:

- typically 100 - 10,000-fold increase in immunoassay sensitivity (LOD)
- high tolerance against drug and biological sample effects
- minimized sample volume (SV)
- broad dynamic range of quantification (QR)



CONCLUSION: In this study the detection of several marker antigens in different biological samples is shown. All biomarkers reveal a good sensitivity (LOD) and a broad dynamic range of quantification (QR) with a regression coefficient of at least $R^2=0.99$. Furthermore the low amount of required sample volume (SV) facilitates study design and permits reliable multiple detections.

Due to the high performance of Imperacer™ this technology could support your work for instance for the early diagnosis of Alzheimer's disease and prognosis of related dementias, including parkinsonian movement disorders. Actually Imperacer™ is used for research and monitoring of Alzheimer's disease in the 2007 launched EU 6th framework Project "EDAR" - (Beta amyloid oligomers in the early diagnosis of AD and as marker for treatment response). However, Imperacer™ is applicable for any biomarker in the CNS field and beyond and could easily be adapted to your target. **Please contact Chimera Biotec for personalized information.**